LMNL - Liminal BioSciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

9.516M

Cash

19.31M

Avg Qtr Burn

-9.03M

Short % of Float

0.05%

Insider Ownership

61.26%

Institutional Own.

0.77%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ryplazim® (plasminogen) Details Congenital Plasminogen Deficiency (C-PLGD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LMNL6511 (GPR84 receptor) Details Non-alcoholic steatohepatitis , Metabolic disorder, Non-Alcoholic Fatty Liver Disease, Idiopathic pulmonary fibrosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fezagepras (PBI-4050) Details Triglycerides	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fezagepras (PBI-4050) Details Rare diseases, Lung disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fezagepras (PBI-4050) Details Rare diseases, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.